The game has changed in biotech. Continued macroeconomic uncertainty has far reaching implications for the biopharma ecosystem. Access to capital remains low across the industry, and a successful deal with large pharma has become less likely for many. Companies who earlier would have been sellers, may now be progressing development through registrational studies — or all the way through to market. Stated another way, biotechs can no longer operate toward the single goal of being acquired by, or of licensing their assets to, large pharma — accordingly, players may need to develop products further than in the past, and therefore strategic pathway optionality needs to be weaved into and maintained throughout product and corporate development. With these new challenges come multifold new opportunities for value creation.
Syneos Health and Treehill Partners are at the center of this landscape, devising concerted product, corporate and business development strategies with customers to navigate the evolving market.
In this webinar, the featured speakers will discuss strategic and operational implications for the biotech C-suite and share perspectives on how companies can succeed in an increasingly competitive environment.
The speakers also look to address some pressing questions such as:
- How far to go as a biotech (and in what circumstances)
- Value focused clinical development
- Strategic capital allocation
- How patients may benefit in the long run from the evolution and increasing sophistication of the biotech ecosystem
Register now to learn about new opportunities for biotechs for value creation.
Lee Taurman, Global Head of Syneos One, Syneos Health
Lee Taurman is an experienced life sciences industry executive and management consultant. He is the Global Head of Syneos One, leading the growth of integrated and innovative offering that spans clinical, medical affairs and commercialization.
Lee specializes in working with clients to develop innovative solutions as they evolve to meet the needs of a changing healthcare and business landscape. This includes developing innovative services and solutions, reorganizing and restructuring to better manage costs and creating new approaches to strategic planning and execution that unlock shareholder value.
Lee previously led Grant Thornton’s advisory practice for Life Sciences. His work with clients focused on creating internal and external innovation platforms to deliver business value. He also developed strategies and execution models to harness the power of the “gig economy” and help manage an increasingly externalized non-employee workforce.
Lee spent over a decade as a management consultant and executive at PricewaterhouseCoopers and IBM Global Business Services where he led the Life Sciences Strategy and Transformation practice.
Keith Ruark, SVP Strategic Business Development, Syneos Health
Keith Ruark is a senior life sciences professional bringing experience in leading tailored asset development and integrated clinical/commercial partnerships.
Keith is an executive leader of the Syneos Health business development organization responsible for structuring strategic partnerships and tailored solutions that leverage global infrastructure and capabilities to maximize value and outcomes for an asset/drug portfolio.
His experience at Syneos Health includes the past four years as one of the principal and founding team members involved in the development of the company’s unique Syneos One business unit as a partnership vehicle from planning through tailored delivery, underpinning a number of unique integrated product development relationships with clients.
Within Keith’s career in life sciences, he has had material involvement in the structuring, negotiation and management of over $500m in product-based and company investments and is part of the working team to set up pharmaceutical product infrastructure.
Ali Pashazadeh, Founder, Treehill Partners
Ali Pashazadeh is a senior biotech strategy advisor and negotiator with a multi-disciplinary strategic mindset. He is ultimately accountable for delivery of client value on all Treehill Partners’ engagements. He is involved as a senior sponsor in a majority of projects and available to clients for strategic and tactical advice.
He puts to work a synthesis of strategic expertise, cross-functional insight and deep hands-on medical understanding when advising clients on their core strategies.
He completed M&A and financing assignments worth above $40 billion, including various landmark transactions in the pharma and biotech sector.
Who Should Attend?
- Business side: corporate development, business development, strategy
- Clinical side: clinical development, medical affairs
Specialty pharma and large pharma:
- SVP level business development, corporate development, strategy
- Business side: corporate development, business development, strategy, mergers & acquisitions
- Clinical side: clinical development, medical affairs, Global Development leadership such as GPT leads
What You Will Learn
- UNDERSTAND the latest trends in the biopharmaceutical market, and the implications for biotech decision makers
- LEARN the potential exits available to biotech and key considerations for creating optionality in the strategic pathway
- DISCOVER best practices for value focused clinical development and strategic capital allocation to optimize asset success
Syneos Health® (Nasdaq:SYNH) is a leading integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.
Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. We support a diverse, equitable and inclusive culture.